Raymond James & Associates’s BlackRock ESG Capital Allocation Term Trust ECAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$1.12M Buy
63,034
+7,443
+13% +$129K ﹤0.01% 2623
2024
Q2
$975K Buy
55,591
+18,519
+50% +$315K ﹤0.01% 2637
2024
Q1
$644K Buy
37,072
+21,569
+139% +$361K ﹤0.01% 2896
2023
Q4
$250K Buy
15,503
+3,026
+24% +$46.1K ﹤0.01% 3398
2023
Q3
$185K Sell
12,477
-5,949
-32% -$91.7K ﹤0.01% 3485
2023
Q2
$289K Sell
18,426
-13,990
-43% -$216K ﹤0.01% 3284
2023
Q1
$506K Buy
32,416
+2,186
+7% +$31.9K ﹤0.01% 2914
2022
Q4
$406K Buy
+30,230
New +$413K ﹤0.01% 3024

Other funds holding ECAT

Raymond James & Associates's ECAT Position: Q3 2024 in Review

Raymond James & Associates increased its BlackRock ESG Capital Allocation Term Trust (ECAT) stake by 13% in Q3 2024, buying an estimated $129K and bringing the position to 63,034 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

Raymond James & Associates first reported a position in ECAT in Q4 2022 and has held it in 8 quarters since. 65 funds tracked by Wall St. Rank hold ECAT as of Q3 2024.

  • Raymond James & Associates held 63,034 shares of BlackRock ESG Capital Allocation Term Trust worth $1.12M as of Q3 2024.
  • Raymond James & Associates bought 7,443 BlackRock ESG Capital Allocation Term Trust shares in Q3 2024, an estimated $129K.
  • BlackRock ESG Capital Allocation Term Trust made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2623 holding.
  • Raymond James & Associates first reported a position in BlackRock ESG Capital Allocation Term Trust in Q4 2022 and has held it in 8 quarters since.
  • 65 funds tracked by Wall St. Rank held BlackRock ESG Capital Allocation Term Trust as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.